Morimatsu 2D WAVE Single-Use Bioreactor Offers Innovative Solutions for Cell Therapy

In the current pharmaceutical field, the market share for cell and antibody therapies is steadily increasing. These therapies hold great promise for patient benefit and medical progress, and are rapidly emerging as effective solutions to complex diseases. As the demand for these cutting-edge drugs grows, it has become a critical challenge to achieve efficient and stable large-scale production. In this process, bioreactors are able to play a crucial role.

Both traditional stainless steel bioreactors and newer single-use bioreactors come equipped with online monitoring and control features. This allows for real-time adjustments to key parameters such as temperature, pH, and dissolved oxygen (DO), helping to optimize the physiological conditions for cell processes and identify the best feeding strategies.

When evaluating bioreactor options, pharmaceutical companies primarily face challenges related to cost (stainless steel/disposable models) and scalability (flow field uniformity and shear force).

❖Stainless steel bioreactors can be difficult to clean, requiring substantial cleaning data during production line changes to comply with GMP standards. This often results in significant time and validation costs for companies.

❖Traditional stirred tank bioreactors can impose high shear stress, making it challenging to culture shear-sensitive cells such as iPSCs, NK cells, and MSCs on a large scale.

Morimatsu 2D WAVE Single-Use Bioreactor is designed to better meet the experimental needs of customers by incorporating advanced foreign technology and cutting-edge design concepts. This bioreactor features a single-use reaction bag, which allows for lower initial investments and eliminates the cleaning time associated with batch changes, significantly reducing contamination risks.

Its unique two-dimensional rocking mode offers gas mass transfer capabilities comparable to traditional stirred tank bioreactors. At the same rotational speed, it generates lower fluid shear stress, creating a gentler growth environment ideal for stem cells and immune cells.

The 2D WAVE Single-Use Bioreactor has successfully facilitated the large-scale culture of HEK293, CHO, and MSC cells. It is capable of maintaining the same or higher cell viability than the stirred tank bioreactor at maximum cell growth density in the same volume.

Experimental results demonstrate that the 2D WAVE Single-Use Bioreactor can support high-density growth of mainstream industrial cell lines. Under appropriate feeding conditions, it features a significantly higher cell proliferation capacity compared to stirred tank bioreactors. For mesenchymal stem cells that require microcarriers for growth, the 2D WAVE Single-Use Bioreactor effectively suspends these microcarriers, providing a uniform physiological environment for MSCs.

Morimatsu is committed to exploring cutting-edge technologies within the industry, using innovation as a driving force to deliver flexible and efficient solutions for biopharmaceutical research, development, and commercial production. This ongoing commitment will empower the high-quality development of the biopharmaceutical sector.